TAKEDA PHARMACEUTICAL CO LTD NPV financial statements, including revenue, expenses, profit, and loss

The total revenue of 0RN3 for the last quarter is 6.43 B EUR, and it's 9.81% lower compared to the previous quarter. The net income of Q4 23 is -18.48 M EUR.